Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +75

Analysts upgrade Elevance, Centene shares as Medicaid margins expected to recover

AI-generated analysis

πŸ“ˆ Bank of America upgraded Elevance Health to Buy from Neutral with a price target of $435.

πŸš€ Centene received a double upgrade from Underperform to Buy, with the price objective raised from $34 to $60.

πŸ“Š Centene shares surged more than 3% in premarket trading following the analyst upgrades.

πŸ’Έ Medicaid reimbursement rates have trailed cost trends since 2023 enrollment shifts, squeezing industry margins.

πŸ“‰ Analysts believe Medicaid margins hit a trough in 2026 and are set for a multi-year recovery.

πŸ” Centene is operating near breakeven in Medicaid, roughly 124% below its long-term target margin.

πŸ’° This margin drag amounts to approximately $4 per share for Centene's 2026 earnings per share (EPS).

🎯 Normalized earnings power for Centene could reach around $12 per share compared to current estimates of $3.40.

πŸ₯ Elevance is guiding to -1.75% Medicaid margins, representing about 37% of its 2026 EPS headwind.

πŸ›‘οΈ Elevance's diversified mix including Carelon and Blue Cross Blue Shield plans provides a risk buffer.

πŸ‘€ The second quarter will be a key test for both companies regarding trend data and enrollment dynamics.

⚠️ Analysts warned that the "One Big Beautiful Bill" could trigger new losses in 2027 or 2028 but are unlikely to cause year-over-year setbacks.

πŸ” Cantor Fitzgerald upgraded Centene to Overweight, citing clearer margin recovery paths and conservative guides.

πŸ’‘ Three factors drove analysts' views: March Wakely report data, net receivable positions, and conservative margins.

πŸ”„ Margin pressure is seen as a pricing cycle issue rather than a structural one for the sector.

πŸ“ˆ Cantor's base case implies over 90% stock appreciation for Centene assuming 3.5% margins by 2028.

βš–οΈ Elevance offers a lower-risk investment theme with an estimated $10 of potential EPS upside despite near-term risks.

Bullish Signals
  • Analysts upgraded Elevance Health and Centene Corporation, with Bank of America raising Elevance from Neutral to Buy at a price objective of $435 and moving Centene from Underperform to Buy.
  • Centene shares rose more than 3% in premarket trading following the upgrades amid growing confidence that Medicaid margins are nearing a trough and set to recover over the next several years.
  • BofA estimates normalized earnings power for Centene could be around $12 per share compared to its current estimate of $3.40, implying significant upside as the company operates near breakeven now but targets 2-4% margins long-term.
  • Despite short-term headwinds, Elevance offers a lower risk investment thesis due to its diversified business mix, including fast-growing Carelon and Blue Cross Blue Shield plans across 14 states, providing $10 of EPS upside.
  • Cantor Fitzgerald upgraded Centene to Overweight with a new price target of $60, noting that margin recovery is simply a matter of timing rather than structural impossibility.
  • Analysts project a base case scenario for Centene with 3.5% margins and 5% top-line growth by 2028, which implies more than 90% stock appreciation from current levels.
Risk Factors
  • Centene is currently operating at breakeven in Medicaid, which is approximately 3% below its long-term target margins, representing a roughly $4 (124%) drag on its 2026 EPS.
  • Elevance Health is guiding to -1.75% Medicaid margins, a significant headwind amounting to about 37% of its projected 2026 EPS.
  • Centene's current earnings are only about 30% of what they should be at target margins, indicating severe underperformance relative to normalized levels of ~$12 per share.
  • The second quarter serves as a critical test period for both companies, with uncertainty still surrounding trend data, exchange risk pools, and Medicaid acuity dynamics.
  • Potential enrollment reductions tied to the 'One Big Beautiful Bill' legislation could spark a new round of losses in 2027 or 2028.
  • State Medicaid reimbursement rates have significantly lagged behind actual cost trends since 2023, squeezing margins across the managed care industry.
Full Analysis
Bank of America upgraded Elevance Health to Buy and gave Centene Corporation a double upgrade on Wednesday, April 29, 2026, driven by increased confidence that Medicaid margins are approaching their trough and poised for recovery over the next several years. BofA raised Elevance's price objective to $435 from Neutral status, while moving Centene to Buy from Underperform with a price target jump to $60 from $34. Following the announcement, Centene shares rose more than 3% in premarket trading. The upgrades reflect the view that state Medicaid reimbursement rates have lagged behind cost trends since the enrollment shifts beginning in 2023, but that margins are bottoming in 2026, making the subsequent recovery a matter of time and math rather than structural change. Centene is currently operating near breakeven in Medicaid, which is roughly 3% below its long-term target margins of 2-4%. Analysts estimate this gap creates approximately a $4 drag, or 124%, on 2026 EPS compared to normalized earnings power of around $12 per share. In contrast, Elevance is guiding to -1.75% Medicaid margins, about 475 basis points below its target midpoint, resulting in an estimated $10 headwind representing 37% of its 2026 EPS. Despite these near-term pressures, Elevance's diversified business mix, including its Carelon health services unit and Blue Cross Blue Shield plans across 14 states, offers a buffer that makes it a lower-risk investment with significant upside potential. Cantor Fitzgerald also upgraded Centene to Overweight and lifted its price target to $60 from $41, citing corroborating data from the March Wakely report, Centene's net receivable position, and conservative guidance on 2026 Medicare and exchange margins as key factors changing their view. Both banks frame the current margin pressure across Medicaid, exchanges, and Medicare as a pricing cycle issue rather than a structural problem. BofA warned that Q2 will be a critical test for both companies due to uncertainties in trend data, exchange risk pools, and Medicaid acuity dynamics, while also noting potential enrollment reductions from the "One Big Beautiful Bill" legislation could spark losses in 2027 or 2028, though unlikely to cause year-over-year setbacks. Cantor's base case assumes 3.5% margins and 5% top-line growth by 2028, implying more than 90% stock appreciation from current levels.